Feb 21, 2018
Lessons from EU Research Funding (1998-2013)
Published in: EU Law and Publications (September 2017). doi: 10.2777/667857
Posted on RAND.org on December 15, 2017
This article was published outside of RAND. The full text of the article can be found at the link above.
The European Commission Research and Innovation Directorate has commissioned a study which seeks to evaluate the role and impact of the European Union's Research Framework Programme activities in the field of Poverty-Related and Neglected Diseases (PRNDs). The study focuses on the impact of past EU funding ([Euro]1.445bn) in PRND research supported from European Union Framework Programmes (FP5-7, 1998-2013), as well as the first European and Developing Countries Clinical Trials Partnership (EDCPT) (2003-2013) and relevant research under the Innovative Medicines Initiative (IMI) (2008-2013). The overarching aim of this work is to evaluate the role of research and development (R&D) on PRNDs in contributing to achieving universal health coverage and improving population health in low- and middle-income countries (LIMCs). Through applying a mixed-methods approach, the evaluation examined the EU portfolio of PRND research, outcomes and impacts associated with EU-funded R&D across different stages of the health innovation pathway and the system-level factors affecting the translation of R&D efforts into universal health coverage (UHC). The evaluation makes nine recommendations addressed to the European Commission, research funders and wider stakeholders in the global health community